CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-01 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $64.70 | $1.3M | 313,226 |
| 2023-08-29 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale | −25,000 | $63.37 | $1.6M | 1,132,620 |
| 2023-08-28 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale | −25,000 | $63.06 | $1.6M | 1,157,620 |
| 2023-08-23 | Gutwerg Ori SVP, GENERICS | Option exercise | +13,502 | $31.49 | $425K | 76,476 |
| 2023-08-23 | Gutwerg Ori SVP, GENERICS | Sale | −13,502 | $62.39 | $842K | 62,974 |
| 2023-08-23 | Gutwerg Ori SVP, GENERICS | Sale | −2,059 | $62.39 | $128K | 60,915 |
| 2023-08-23 | Gutwerg Ori SVP, GENERICS | Option exercise · Stock Option (right to buy) | −13,502 | $31.49 | $425K | 13,504 |
| 2023-08-23 | Marken James G. SVP OPS & PROD DEV | Option exercise | +3,750 | $40.59 | $152K | 135,377 |
| 2023-08-23 | Marken James G. SVP OPS & PROD DEV | Option exercise | +1,667 | $33.00 | $55K | 137,044 |
| 2023-08-23 | Marken James G. SVP OPS & PROD DEV | Sale | −3,932 | $63.00 | $248K | 133,112 |
| 2023-08-23 | Marken James G. SVP OPS & PROD DEV | Option exercise · Stock Option (right to buy) | −3,750 | $40.59 | $152K | 0 |
| 2023-08-23 | Marken James G. SVP OPS & PROD DEV | Option exercise · Stock Option (right to buy) | −1,667 | $33.00 | $55K | 0 |
| 2023-08-21 | Leonard Matthew J Director | Grant or award | +7,583 | 7,583 | ||
| 2023-08-16 | MERIDIAN VENTURE PARTNERS II LP 10% owner | Sale | −200,000 | $58.50 | $11.7M | 1,819,259 |
| 2023-08-15 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −22,110 | $61.60 | $1.4M | 1,182,620 |
| 2023-08-15 | Lalwani Nikhil PRESIDENT & CEO | Option exercise | +11,616 | $29.00 | $337K | 365,006 |
| 2023-08-15 | Lalwani Nikhil PRESIDENT & CEO | Sale | −11,616 | $61.13 | $710K | 353,390 |
| 2023-08-15 | Lalwani Nikhil PRESIDENT & CEO | Option exercise · Stock Option (right to buy) | −11,616 | $29.00 | $337K | 168,027 |
| 2023-08-14 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −27,890 | $61.15 | $1.7M | 1,204,730 |
| 2023-08-14 | CAREY STEPHEN P. SVP & CFO | Sale | −17,639 | $61.37 | $1.1M | 155,839 |
Page 18 of 23 · 442 trades